The Current Landscape of Repurposed Drugs for Fungal Neglected Tropical Diseases
Abstract
PURPOSE OF REVIEW: Eumycetoma, chromoblastomycosis, and sporotrichosis are three of only four fungal infections recognized as Neglected Tropical Diseases (NTDs) by the World Health Organization. They are a significant source of morbidity in subtropical and tropical regions of the Americas, Africa, and Asia. There are very few treatments approved for these diseases. Clinicians often use drug repurposing, off-label use of existing drugs, for their treatment. This article is a systematic review of the published literature on the treatment of fungal NTDs from the last five years (2019-2024). It will provide an overview for each fungal NTD, their current treatment landscape, and the challenges associated with their treatment.
RECENT FINDINGS: Itraconazole remains the most widely used antifungal for the treatment of these fungal NTDs. Newer antifungals such as fosravuconazole have matched the efficacy of currently available drugs while reducing adverse events and pill burden. Other promising treatment strategies involve the use of immunomodulators (e.g., imiquimod), steroids (e.g., prednisolone), or non-steroidal anti-inflammatory agents in combination with traditional antifungal agents.
SUMMARY: Frequently repurposed drugs include itraconazole, posaconazole, voriconazole, amphotericin B, terbinafine, potassium iodide, and 5-flucytosine. Most of these drugs have significant side effects, unsatisfactory cure rates, and significant cost that restricts their use. Systematic…
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.